6533b83afe1ef96bd12a788e

RESEARCH PRODUCT

Pathogenese und Therapie des akuten Koronarsyndroms differenzieller Nutzen von GPIIb/IIIa-Rezeptorantagonisten bei Hochrisikopatienten

subject

description

Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients Activated thrombocytes and their aggregation into a thrombus play a decisive role in the pathogenesis of the acute coronary syndrome. Glycoprotein (GP) IIb/IIIa receptor antagonists block the binding of fibrinogen to GP IIb/IIIa receptors of activated thrombocytes and inhibit their aggregation. Patients with an acute coronary syndrome and raised troponin levels who are to undergo primary coronary revascularization profit particularly from treatment with GPIIb/IIIa receptor antagonists. This is especially so if they also have diabetes.